Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00458848
Status:
COMPLETED
Last Update Posted:
2019-02-15
First Post:
2007-04-09
Brief Title:
Chemotherapy With or Without Imatinib andor Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
Sponsor:
Gruppo Italiano Malattie EMatologiche dellAdulto
Organization:
Gruppo Italiano Malattie EMatologiche dellAdulto
Study Overview
Official Title:
Phase II Study of Adult Acute Lymphoblastic Leukaemia ALL Imatinib in Combination With Chemotherapy in Ph Patients and Post-remissional Treatment Intensification in High-risk Ph- Patients With Minimal Residual Disease Monitoring
Status:
COMPLETED
Status Verified Date:
2018-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LAL0904
Brief Summary:
RATIONALE Drugs used in chemotherapy work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy When the healthy stem cells are infused into the patient they may help the patients bone marrow make stem cells red blood cells white blood cells and platelets Giving combination chemotherapy together with imatinib mesylate and peripheral stem cell transplant may be an effective treatment for acute lymphoblastic leukemia
Nevertheless in the last few years GIMEMA has pubblished a paper in which 100 of Ph ALL patients reach HCR only with Imatinib without any chemiotherapy Thus this treatment will be implemented in patients pertaining to this category
Nevertheless in the last few years GIMEMA has pubblished a paper in which 100 of Ph ALL patients reach HCR only with Imatinib without any chemiotherapy Thus this treatment will be implemented in patients pertaining to this category
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LAL0904 | OTHER | None | None |
| 2004-001738-11 | OTHER | EudraCT | None |